Corticotropin
- Generic Name
- Corticotropin
- Brand Names
- Acthar, Cortrophin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12427-33-7
- Unique Ingredient Identifier
- K0U68Q2TXA
- Background
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
- Indication
For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.
- Associated Conditions
- Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis
- Associated Therapies
- -
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Southeast Renal Research Institute
- Target Recruit Count
- 15
- Registration Number
- NCT01028287
- Locations
- 🇺🇸
Southeast Renal Research Institute, Chattanooga, Tennessee, United States
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Neurologique Foundation, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00947895
- Locations
- 🇺🇸
Neurologique Foundation, Inc., Ponte Vedra, Florida, United States
Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Elliot Frohman
- Target Recruit Count
- 1
- Registration Number
- NCT00854750
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT00805753
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦University of Toronto, Toronto, Ontario, Canada
Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock
- Conditions
- Septic Shock
- First Posted Date
- 2000-06-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 56
- Registration Number
- NCT00005890
- Locations
- 🇺🇸
Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States
Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment
- Conditions
- Spasms, InfantileEpilepsy
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 30
- Registration Number
- NCT00004758
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.